Analyzing bacterial overgrowth in pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to prospectively analyze the prevalence of small intestinal bacterial overgrowth (SIBO) in patients diagnosed with pancreatic adenocarcinoma (PDAC) who are experiencing clinically significant weight loss. The study will enroll 100 patients and utilize the Lactulose Hydrogen Breath Test to assess SIBO presence. Additionally, it will explore the association between SIBO prevalence and the patients' pancreatic resection status. The findings could enhance understanding of the gastrointestinal complications faced by PDAC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men, Women, and all genders
* Individuals 18 years old or older are included.
* Patients of the study investigators and team members
* Diagnosis of pancreatic ductal adenocarcinoma
* All subjects must consent to this study
* Clinically diagnosed weight loss

Exclusion Criteria:

* Minors
* Pregnant Women
* Any records flagged "break the glass" or "research opt out."
* Patients who have received treatment for SIBO in the past 3 months

Where it's running

• Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Andrew E. Hendifar, M.D., M.P.H. — Cedars-Sinai Medical Center
• Study coordinator: Clinical Trials Navigator
• Email: GroupCancerTrialInformation@cshs.org
• Phone: 310-423-2133

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 15-year outcomes after sleeve gastrectomy in France

  This study looks at how people who had sleeve gastrectomy have fared over 15 years to see long-term weight changes and health effects.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07883018

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Do GLP-1 medicines affect breastmilk production and milk quality after pregnancy

  This study will test whether weight loss from injected GLP-1 receptor agonists changes how much milk moms produce or the nutritional makeup of their breast milk.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07720414

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.